Stock Markets April 22, 2026 09:50 AM

UBS Raises Biogen to Buy, Cites Multiple Near-Term Pipeline Catalysts Driving Potential Upside

Analyst highlights concentrated 12-15 month catalyst window and applies 14x P/E on 2027 earnings to set $225 target

By Maya Rios BIIB
UBS Raises Biogen to Buy, Cites Multiple Near-Term Pipeline Catalysts Driving Potential Upside
BIIB

UBS analyst Michael Yee upgraded Biogen from Neutral to Buy and lifted the price target to $225 from $185, pointing to a cluster of pipeline catalysts over the next 12 to 15 months that UBS believes are not fully reflected in the stock. The firm sees 25% to 50% upside from current levels versus roughly 20% downside, and applies a 14 times P/E multiple on 2027 estimated earnings of $16.53 to derive the target.

Key Points

  • UBS upgraded Biogen to Buy and raised the price target to $225 from $185, applying a 14x P/E on 2027 estimated earnings of $16.53.
  • The firm identifies a 12-15 month window of four pipeline catalysts - BIIB080 tau data, Phase III litifilimab in SLE, cutaneous lupus data, and Phase III felzartamab in antibody-mediated rejection - as drivers of potential upside.
  • Sectors impacted include biotechnology, pharmaceuticals, and healthcare equities due to potential shifts in valuation and clinical development outcomes.

UBS analyst Michael Yee has moved Biogen up to a Buy recommendation from Neutral and increased the firm's price target to $225 from $185 in a note released on Wednesday. The upgrade is driven by what UBS characterizes as a concentrated sequence of clinical and data milestones over the next 12 to 15 months that the market may not have fully priced.

Yee notes that Biogen appears discounted versus large-cap peers, trading at about 11 times estimated 2027 earnings compared with a group mean of 15 times. He describes the shares as an "underowned, out-of-favor stock" and frames the valuation gap as a key part of the bullish thesis.

UBS quantifies the risk-reward as approximately 25% to 50% upside from current levels against roughly 20% downside.

The UBS bullish case is anchored by four primary catalysts:

  • BIIB080 tau data expected this summer. UBS acknowledges the trial was downsized and that statistical significance is unlikely, but it points to encouraging PET tau reduction trends and assigns an asymmetrical outcome expectation - upside skewed more than downside. UBS frames the potential move as up 10-25% versus a downside of maybe 5-10% based on these trends.
  • Phase III litifilimab data in systemic lupus erythematosus (SLE) due in the fourth quarter. UBS treats this as a more material catalyst, assigning a 65% probability of success and projecting peak sales north of $1 billion in that indication alone. The firm estimates positive Phase III results could propel the stock 20% or more.
  • Additional data for cutaneous lupus erythematosus expected mid-2027. UBS describes this indication as "wide open with no approved therapies," highlighting the potential commercial opportunity if data are positive.
  • Phase III felzartamab data in antibody-mediated rejection following kidney transplant due in the first half of 2027. UBS assigns a 55% to 60% probability of success to this program.

To reach its $225 target, UBS applies a 14 times price-to-earnings multiple to Biogen's 2027 estimated earnings of $16.53 per share. That calculation supports the firms revised valuation and underpins the upgrade.


Below are the key takeaways and considerations stemming from UBSs note, focused on valuation, the timing of near-term readouts, and the range of outcomes UBS models for Biogens pipeline catalysts.

Risks

  • BIIB080 tau readout this summer is from a downsized trial; UBS notes statistical significance is unlikely, and there is potential downside if PET tau reduction trends do not translate into meaningful results - impacting biotech sector sentiment.
  • Phase III data for litifilimab in systemic lupus erythematosus carries binary risk despite a 65% probability of success assigned by UBS; a negative outcome could pressure Biogen shares and affect pharmaceutical and specialty therapeutic stocks.
  • Felzartamab Phase III results in antibody-mediated rejection are assigned a 55% to 60% probability of success by UBS, indicating material clinical execution risk that could influence midstream biotech valuations in transplant-related therapies.

More from Stock Markets

U.S. Commerce Secretary: Nvidia’s H200 Chips Have Not Been Sold to Chinese Firms Yet Apr 22, 2026 United Says Ticket Prices May Rise Up to 20% as Jet Fuel Costs Surge Apr 22, 2026 Warsaw stocks dip as banking, construction and chemicals weigh on market Apr 22, 2026 Istanbul bourse slips as insurance, sports and basic metals drag indexes down Apr 22, 2026 Copenhagen market edges lower as select sectors weigh on OMX Copenhagen 20 Apr 22, 2026